筛选条件 共查询到69条结果
排序方式
GRK2 regulates ADP signaling in platelets via P2Y(1) and P2Y(12)

期刊: BLOOD ADVANCES, 2022; 6 (15)

The critical role of G protein-coupled receptor kinase 2 (GRK2) in regulating cardiac function has been well documented for > 3 decades. Targeting ......

JIF:5.486

CPT2 K79 acetylation regulates platelet life span

期刊: BLOOD ADVANCES, 2022; 6 (17)

The short life span of platelets is a major challenge to platelet transfusion services because of the lack of effective intervention. Here, we found t......

JIF:5.486

Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma

期刊: BLOOD ADVANCES, 2022; 6 (6)

The non-germinal center B-cell like (non-GCB) subtype of diffuse large B-cell lymphoma (DLBCL) has poor clinical outcomes. Bruton tyrosine kinase (BTK......

JIF:5.486

Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH

期刊: BLOOD ADVANCES, 2022; 6 (2)

Single-cell analysis is of significant importance in delineating the exact phylogeny of the subclonal population and in discovering subtle diversifica......

JIF:5.486

Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study

期刊: BLOOD ADVANCES, 2022; 6 (14)

Intracranial hemorrhage (ICH) is a rare and life-threatening hemorrhagic event in patients with immune thrombocytopenia (ITP). However, its mortality ......

JIF:5.486

Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma

期刊: BLOOD ADVANCES, 2022; 6 (3)

Single antigen-targeted chimeric antigen receptor (CAR) T-cell therapy maybe insufficient to induce a durable response in pediatric aggressive B-cell ......

JIF:5.486

Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients

期刊: BLOOD ADVANCES, 2022; 6 (9)

Hepatitis B virus (HBV) infection has been associated with an increased risk for B-cell lymphomas. We previously showed that 20% of diffuse large B-ce......

JIF:5.486

Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma

期刊: BLOOD ADVANCES, 2022; 6 (1)

The malignant plasma cell clone in patients with multiple myeloma (MM) is represented by the production of paraprotein, usually a single abnormal uniq......

JIF:5.486

Genome-wide CRISPR/Cas9 screening identifies determinant of panobinostat sensitivity in acute lymphoblastic leukemia

期刊: BLOOD ADVANCES, 2022; 6 (8)

Epigenetic alterations, including histone acetylation, contribute to the malignant transformation of hematopoietic cells and disease progression, as w......

JIF:5.486

CD44-fibrinogen binding promotes bleeding in acute promyelocytic leukemia by in situ fibrin(ogen) deposition

期刊: BLOOD ADVANCES, 2022; 6 (15)

Early hemorrhagic death is still the main obstacle for the successful treatment of acute promyelocytic leukemia (APL). However, the mechanisms underly......

JIF:5.486

Inflammation accelerates BCR-ABL1(+) B-ALL development through upregulation of AID

期刊: BLOOD ADVANCES, 2022; 6 (13)

Inflammation contributes to the initiation and disease progression of several lymphoid malignancies. BCR-ABL1-positive B-cell acute lymphoblastic leuk......

JIF:5.486

Landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance to LPL/WM

期刊: BLOOD ADVANCES, 2022; 6 (13)

Lymphoplasmacytic lymphoma/Waldenstroeurom macroglobulinemia (LPL/WM) is a heterogeneous disease in which the role of immunoglobulin heavy-chain genes......

JIF:5.486

Upregulated SPAG6 promotes acute myeloid leukemia progression through MYO1D that regulates the EGFR family expression

期刊: BLOOD ADVANCES, 2022; 6 (18)

Chromosomal aberrations and gene mutations have been considered to be the major reasons for high recurrence rates and poor survival among acute myeloi......

JIF:5.486

共69条页码: 1/5页15条/页